1
Stéphane De Lombaert
Rajagopal Bakthavatchalam, Charles A Blum, Harry L Brielmann, James William Darrow, Stéphane De Lombaert, Alan Hutchison, Jennifer Tran, Xiaozhang Zheng, Richard Louis Elliott, Marlys Hammond: Spiro[isobenzofuran-1,4′-piperidin]-3-ones and 3H-spiroisobenzofuran-1,4′-piperidines. Pfizer, Neurogen Corporation, Ladas & Parry, May 20, 2003: US06566367 (53 worldwide citation)

Substituted spiro[isobenzofuran-1,4′-piperidin]-3-ones and 3H-spiroisobenzofuran-1,4′-piperidines capable of modulating NPY5 receptor activity are provided. Such compounds may be used to modulate ligand binding to NPY5 receptors in vivo or in vitro, and are particularly useful in the treat ...


2
Stéphane De Lombaert
Rajagopal Bakthavatchalam, Charles A Blum, Stéphane De Lombaert, Taeyoung Yoon, Xiaozhang Zheng: Biaryl piperazinyl-pyridine analogues. Neurogen Corporation, Edwards Angell Palmer & Dodge, Peter F Corless, Mark D Russett, July 28, 2009: US07566712 (6 worldwide citation)

Biaryl piperazinyl-pyridine analogues are provided, of the Formula: wherein variables are as described herein. Such compounds are ligands that may be used to modulate specific receptor activity in vivo or in vitro, and are particularly useful in the treatment of conditions associated with pathologic ...


3
Stéphane De Lombaert
Rajagopal Bakthavatchalam, Timothy M Caldwell, Bertrand L Chenard, Stéphane De Lombaert, Kevin J Hodgetts: Substituted quinolin-4-ylamine analogues. Neurogen Corporation, Edwards Angell Palmer & Dodge, Peter F Corless, Mark D Russett, February 10, 2009: US07488740 (5 worldwide citation)

Substituted quinolin-4-ylamine analogues are provided. Such compounds are ligands that may be used to modulate specific receptor activity in vivo or in vitro, and are particularly useful in the treatment of conditions associated with pathological receptor activation in humans, domesticated companion ...


4
Stéphane De Lombaert
Rajagopal Bakthavatchalam, Charles A Blum, Harry Brielmann, Timothy M Caldwell, Stéphane De Lombaert, Kevin J Hodgetts, Xiaozhang Zheng, Taeyoung Yoon: Substituted quinazolin-4-ylamine analogues. Neurogen Corporation, Edwards Angell Palmer & Dodge, Peter F Corless, Mark D Russett, December 4, 2007: US07304059 (3 worldwide citation)

Substituted quinazolin-4-ylamine analogues are provided. Such compounds are ligands that may be used to modulate specific receptor activity in vivo or in vitro, and are particularly useful in the treatment of conditions associated with pathological receptor activation in humans, domesticated compani ...


5
Stéphane De Lombaert
Rajagopal Bakthavatchalam, Charles A Blum, Harry Brielmann, Stéphane De Lombaert, Xiaozhang Zheng: Substituted (7-pyridyl-4-phenylamino-quinazolin-2-yl)-methanol analogues. Neurogen Corporation, Edwards Angell Palmer & Dodge, Peter F Corless, Mark D Russett, February 12, 2008: US07329664 (2 worldwide citation)

Substituted (7-pyridyl-4-phenylamino-quinazolin-2-yl)-methanol analogues are provided. Such compounds are ligands that may be used to modulate specific receptor activity in vivo or in vitro, and are particularly useful in the treatment of conditions associated with pathological receptor activation i ...


6
Stéphane De Lombaert
Rajagopal Bakthavatchalam, Timothy M Caldwell, Bertrand L Chenard, Stéphane De Lombaert, Kevin J Hodgetts: Substituted quinolin-4-ylamine analogues. Neurogen Corporation, Edward Angell Palmer & Dodge, November 19, 2009: US20090286767-A1

Substituted quinolin-4-ylamine analogues are provided. Such compounds are ligands that may be used to modulate specific receptor activity in vivo or in vitro, and are particularly useful in the treatment of conditions associated with pathological receptor activation in humans, domesticated companion ...


7
Paul Edward Aldrich, Argyrios Georgios Arvanitis, Rajagopal Bakthavatchalam, James Peter Beck, Robert Scott Cheeseman, Robert John Chorvat, Paul Joseph Gilligan, Carl Nicholas Hodge, Zelda Rakowitz Wasserman: 1N-alkyl-N-arylpyrimidinamines and derivatives thereof. Dupont Pharmaceuticals Company, Monte R Browder, Kenneth B Rubin, August 22, 2000: US06107301 (56 worldwide citation)

The present invention provides novel compounds, compounds and pharmaceutical compositions thereof, and methods of using same in the treatment of affective disorders, anxiety, depression, post-traumatic stress disorders, eating disorders, supranuclear palsy, irritable bowel syndrome, immune suppressi ...


8

9
Rajagopal Bakthavatchalam, Charles A Blum, Harry Brielmann, Timothy M Caldwell, Stephane De Lombaert, Kevin J Hodgetts, Xiaozhang Zheng: Substituted quinazolin-4-ylamine analogues. Neurogen Corporation, Peter F Corless, John B Alexander, Edwards Angell Palmer & Dodge, July 11, 2006: US07074799 (22 worldwide citation)

Substituted quinazolin-4-ylamine analogues are provided. Such compounds are ligands that may be used to modulate specific receptor activity in vivo or in vitro, and are particularly useful in the treatment of conditions associated with pathological receptor activation in humans, domesticated compani ...


10
Richard Gerald Wilde, Rajagopal Bakthavatchalam, James Peter Beck, Argyrios Georgious Arvanitis: Imidazopyrimidines and imidazopyridines for the treatment of neurological disorders. Dupont Pharmaceuticals Company, Monte R Browder, Maureen P O Brien, Kenneth B Rubin, November 7, 2000: US06143743 (18 worldwide citation)

Corticotropin releasing factor (CRF) antagonists of formula (I): ##STR1## and their use in treating psychiatric disorders and neurological diseases, anxiety-related disorders, post-traumatic stress disorder, supranuclear palsy and feeding disorders as well as treatment of immunological, cardiovascul ...



Click the thumbnails below to visualize the patent trend.